Oral leukoplakia: Diagnosis and treatment by Kjaergaard Larsen, Marie et al.
Received: 17 May. 2015 Accepted: 22 Aug. 2015 
 
1- Department of Oral and Maxillofacial Surgery, Odense University Hospital, Odense, Denmark 
2- Professor, Department of Plastic and Reconstructive Surgery, Odense University Hospital, Odense, Denmark 
3- Professor, Department of ORL-Head and Neck Surgery, Odense University Hospital, Odense, Denmark 
4- Associate Professor, Department of Oral and Maxillofacial Surgery, Odense University Hospital, Odense, Denmark 
Correspondence to: Marie Kjaergaard Larsen, DDS 
Email: mkjaergaard@me.com  
 
 
 
http://johoe.kmu.ac.ir,    3 April 
       J Oral Health Oral Epidemiol/ Spring 2016; Vol. 5, No. 2      57 
Oral leukoplakia: Diagnosis and treatment 
 
Marie Kjaergaard Larsen DDS1, Jens Ahm Sørensen MD, PhD2,  
Christian Godballe MD, PhD3, Torben Henrik Thygesen DDS, PhD4 
 
Abstract 
BACKGROUND AND AIM: Oral leukoplakia (OL) is a common premalignant lesion. The possible benefits of specific 
interventions in preventing a malignant transformation of OL are not well understood. This review assesses different 
invasive treatment techniques for OL and evaluate the optimal treatment possibilities. 
METHODS: A Medline (PubMed) search was conducted and heterogeneity between the studies was found, e.g., with 
regard to the OL lesions, patient groups, follow-up time, and definition of recurrence. 
RESULTS: The recurrence and malignant transformation rate after the different treatment methods were evaluated. The 
mean overall recurrence rate varied with the treatment method. 
CONCLUSION: A surgical treatment appears to decrease the risk of transformation but does not fully eliminate it. 
Follow-up should be done regardless of the surgical treatment. 
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he incidence of oral cancer varies 
among countries and is generally 
increasing.1-3 The most common 
type is the squamous cell carcinoma 
(SCC), which in the United States accounts 
for 96% of the oral cancers.1 The etiological 
basis for the SCC is not known-human 
papilloma virus and the use of marijuana has 
been suggested.4 An increased focus on 
premalignant conditions, risk factors, and 
relevant treatment opportunities is imperative. 
In spite of decreasing the incidence of 
developing oral SCC, this review will base on 
the treatment of the premalignant condition 
and oral leukoplakia (OL). 
A premalignant condition is a pathological 
process that possesses the ability to develop 
into a malignancy. In 1967, the World Health 
Organization (WHO) established a center for 
characterizing and defining which oral 
lesions should be considered premalignant 
and to determine the risk of these lesions 
becoming malignant.5 One of the most 
common lesions is leukoplakia. OL was 
defined by the WHO in 1978 as: “a white 
patch or plaque that cannot be characterized 
clinically or pathologically as any other 
disease.”5 The definition of OL has changed 
over the years and in 2005 it was defined as: 
“white plaques of questionable risk having 
excluded (other) known diseases or disorders 
that carry no increased risk for cancer.”6 
OL has the potential risk of a malignant 
transformation into SCC. The prevalence of OL 
varies from 0.9 to 3%7-9 with a malignant 
transformation rate of 0.13-37%.9-15 The 
incidence of OL displays geographic and 
demographic variations thus resembling the 
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incidence of oral cancer.16 The reported 
proportion of OL that transforms into 
carcinoma varies depending on several factors, 
e.g., the definition of OL, the study population, 
and the length of observation time. The main 
risk factors for developing OL are tobacco 
smoking, betel quid chewing, and alcohol 
consumptions.11,17-23 It is unclear whether these 
risk factors play a role in the malignant 
transformation of OL. The studies show that 
there is a higher risk of malignant 
transformation of OL in older persons than in 
younger persons when the OL is located on the 
lateral/ventral tongue, and non-homogenous 
lesions have a higher transformation rate than 
homogenous lesions.10-12,21,24,25  
The high-risk sites for developing SCC 
might be explained on the basis of a higher 
exposure to carcinogens than other areas of 
the oral cavity and the lower degree of 
keratinization.26,27 Holmstrup et al.28 showed 
that the risk of non-homogenous OL 
undergoing malignant transformation was 
seven times greater than it was for 
homogenous OL. Furthermore, they showed a 
5 times increased risk for malignant 
development when the size of the OL 
exceeded 20 cm2.28 Another study reported a 
higher potential for malignant development of 
widespread OL than for smaller, localized 
OLs.27 
The histological presence of epithelial 
dysplasia is often correlated with a higher risk 
of cancerous transformation.11,21,24,29 A meta-
analysis from 2009 showed that the malignant 
transformation rate of lesions with oral 
dysplasia was 12.1%.30 Holmstrup et al.28 
showed that 11-14% of lesions exhibiting slight 
epithelial dysplasia, developed into cancer. 
Methods 
This article focuses on OL treatment methods 
and their outcome. A web-based search was 
done using the National Center for 
Biotechnology Information (NCBI) to search 
Medline (PubMed). The use of PubMed was 
chosen according to the searching procedure 
and references. The keyword “OL” was used. 
A total number of 4315 titles were identified, 
and 252 titles and abstracts were recognized 
as potentially appropriate. The articles 
containing human immunodeficiency virus 
(HIV) and those not in English were 
excluded. Inclusion criteria were malignant 
transformation, diagnostic, treatment, and 
outcome. Furthermore, a thorough 
bibliographic hand search identified further 
studies. Due to the fact that only a few 
randomized clinical trials (RCTs) exist, 
retrospective non-RCTs were included. 
Results 
A full-text screening of 175 papers was 
performed according to the inclusion and 
exclusion criteria. 30 papers were included 
(Tables 1-4). Data from clinical articles were 
compared with regard to number of patients, 
clinical resolution of OL, follow-up, 
recurrence, and malignant transformation.  
The clinical and histological appearance of OL 
Clinically, OL varies in size, shape, and 
consistency. OL is often divided into 
homogenous and non-homogenous lesions.  
 
Table 1. Results of observation in oral leukoplakia (OL) in the literature 
Author Year 
Number of 
patients 
Follow-up 
(months) 
Clinical 
resolution (%) 
Malignant 
transformation (%) 
Silverman et al.
12
 1984 196 6-468 NR 17.5 (including 61 patients 
treated surgically) 
Holmstrup et al.
28
 2006 175 18-223.2 16.0 4.00 
Banoczy and Csiba
31
 1976 23 12-240 0.0 30.40 
Saito et al.
32
 2001 51 7-192 NR 7.80 
Silverman et al.
33
 1976 4762 24 31.6 0.13 
5 studies   7-468 0-31.6 0-30.4 
NR: Not report 
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Table 2. Results of surgical excision in oral leukoplakia (OL)‎ in the literature 
Author Year 
Number of 
patients 
Follow-up 
(months) 
Recurrence 
(%) 
Malignant 
transformation (%) 
Silverman et al.
12
 1984 61 6-468 34.4 17.5 (including 196 
patients non-treated) 
Holmstrup et al.
28
 2006 94 18-223.2 13.0 12.0 
Vedtofte et al.
34
 1987 46 Average 46.8 17.4 6.5 
Pandey et al.
35
 2001 59 12-37 10.1 0.0 
Hogewind et al.
36
 1989 46 12-100 0.0 3.6 
Banoczy and Csiba
31
 1976 45 12-240 NR 2.2 
Hsue et al.
37
 2007 166 Mean 43.2 NR 4.8 
Saito et al.
32
 2001 75 7-192 NR 1.3 
del Corso et al.
38
 2015 30 6-112 13.3 0.0 
9 studies   6-223.2 0-34.4 0-12 
NR: Not report 
 
Homogenous leukoplakia is flat and may 
exhibit superficial irregularities. The non-
homogenous lesion is mostly white but can be 
white and red with an irregular texture that can 
be flat, nodular, or speckled. The homogenous 
lesion may be white, whitish yellow, or gray, 
and can vary greatly in size.5,57,58Non-
homogenous OL may compromise about 10% 
of all OL.59 ethiologic factors associated with 
OL, e.g., candidiasis, smoker’s lesions, 
frictional lesions, and dental-restoration 
associated lesions and can show white 
plaques or patches and must be identified 
before making the diagnose of OL.58,60 
Histologically, OL shows variable degrees 
of hyperorthokeratosis, hyperparakeratosis, 
acanthosis, and atrophy. Furthermore, a 
diffuse chronic inflammatory infiltration in 
the lamina propria is often seen. Dysplasia 
may be seen occasionally.59 Apart from the 
nodular type of OL, there is not a strong 
correlation between clinical appearance and 
dysplasia.5 The presence of dysplasia may 
indicate an increased risk of the malignant 
transformation. The dysplasia is graded as 
mild, moderate and severe dysplasia and 
carcinoma in situ.13,59 Currently, no 
reproducible criteria exist that can be used to 
divide the dysplastic spectrum into mild, 
moderate or severe.61 The grade of dysplasia 
is subjective and dependent on the 
pathologist.24,61,62 Silverman et al.12 showed 
that 8.6% of the patients with OL had a 
diagnosis of epithelial dysplasia.The benefit 
of a subdivision of epithelial dysplasia is not 
known.5,59,61 
 
Table 3. Results of cryosurgery in oral leukoplakia (OL)‎ ‎in the literature 
Author Year Therapy 
Number 
of 
patients 
Clinical 
resolution 
(%) 
Follow-
up 
(months) 
Recurrence 
(%) 
Malignant 
transformation 
(%) 
Yeh
39
 2000 Cryosurgery (open) 
(liquid nitrogen) 
25 NR 3-46 32.0 NR 
Kawczyk-
Krupka et al.
40
 
2013 Cryosurgery 
(closed) 
(nitrousoxide) 
37 89.2 6 24.3 5.4 
Yu et al.
41
 2009 Cryosurgery (open) 
(liquid nitrogen) 
47 All 5-31 8.3 0.0 
Lin et al.
42
 2012 Cryosurgery 
(closed) (liquid 
nitrogen) 
54 All 7-38 8.3 0.0 
Saito et al.
32
 2001 Cryosurgery 
(closed) (liquid 
nitrogen) 
12 All 7-192 25.0 25.0 
5 studies    89.2-100% 3-192 8.3-32 0-25 
NR: Not report 
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Table 4. Results of laser treatment in oral leukoplakia (OL)‎ ‎in the literature 
Author Year Therapy 
Number of 
patients 
Follow-up 
(months) 
Recurrence 
(%) 
Malignant 
transformation (%) 
Yang et al.
21
 2011 CO2 114 21-110 17.5 11.4 
Chandu and 
Smith
22
 
2005 CO2 43 2-102 28.9 7.3 
Schoelch et al.
43
 1999 CO2 
Nd: YAG 
70 (55) 6-178 38.2 9.0 
Thomson and 
Wylie
44
 
2002 CO2 57 1-44 33.3 7.0 
Frame
45
 1985 CO2 (vaporization 
or evaporation) 
75 3-45 8.0 NR 
Horch et al.
46
 1986 CO2 (evaporation) 32 37 22 NR 
Ishii et al.
47
 2003 CO2 
Nd: YAG 
KTP 
82 6-288 29.3 1.2 
White et al.
48
 1998 CO2 
Nd: YAG 
17 
22 
1-36 23.5 
27.2 
NR 
López-Jornet 
and Camacho-
Alonso
49
 
2013 CO2 
Kirurgi 
48 1-40 NR 0 
Vivek et al.
50
 2008 Nd: YAG 28 60 7 3.5 
van der Hem et 
al.
51
 
2005 CO2 200 1-219 9.9 1.1 
Flynn et al.
52
 1988 CO2 
(vaporization) 
14 12-41 15 NR 
Chiesa et al.
53
 1990 CO2 (vaporization 
or evaporation) 
145 12-36 10 (12 months) 
21 (24 months) 
27 (36 months) 
1.4 
Roodenburg et 
al.
54
 
1991 CO2 70 6-144 9.7 NR 
Lim et al.
55
 2010 CO2 
KTP 
75 41-43 39.5 (CO2) 
25 (KTP) 
4 (CO2) 
5.4 (KTP) 
Mogedas-
Vegara et al.
56
 
2015 CO2 
(vaporization) 
65 0.3-38.7 33.8 15.4 
del Corso  
et al.
38
 
2015 Nd: YAG 47 6-112 38.3 3.9 
17 studies    0.3-288 7-39.5 0-15.4 
KTP: Potassium-titanyl-phosphate; Nd: YAG: Neodymium: yttrium-aluminum garnet; CO2: Carbon dioxide; NR: Not report 
 
Malignant transformation 
Clinically, almost all oral cancers have two 
characteristic features: ulceration and an 
indurated margin, although these features 
may not be present in the early stages of oral 
cancers.59 A diagnose of SCC is made 
histopathologically when the nests of 
epithelial cells have invaded the underlying 
lamina propria and deeper submucosa.5,59 
The most important predictor of 
recurrence and mortality in patients with 
SCC is the clinical stage at the time of 
diagnosis.13,59 The early detection and 
treatment of premalignant lesions can help 
prevent transformation into oral carcinoma. 
Several methods are available for the 
screening of oral cancer and precancerous 
lesions. Unfortunately, most methods present 
limitations that make them more or less 
useful.13,59,63,64 
Conventional oral examination and 
palpation remain the standard method for 
screening of oral cancer and premalignant 
lesions.  
Biopsy and histopathological examination 
are the gold standard in diagnosing and 
grading oral premalignant lesions.13,63,65-67 
Invasive methods can be painful and can 
result in complications. Non-invasive tests 
 
 
 
 
 
http://johoe.kmu.ac.ir,    3 April 
Larsen et al. Oral leukoplakia: Diagnosis and Treatment 
       J Oral Health Oral Epidemiol/ Spring 2016; Vol. 5, No. 2      61 
would be preferable as a diagnostic tool, and 
various tests are now being investigated. 
Toluidine blue (tolonium chloride) can be 
used to identify premalignant and 
carcinomatous lesions. The dye is a member 
of the thiazine group and it selectively stains 
acid tissue components such as DNA and 
RNA. Theoretically, dysplastic and malignant 
cells have a higher RNA and DNA content 
than normal cells, which is the rationale for 
its use.63 Toluidine blue can help identify the 
presence of dysplastic or carcinomatous 
lesions, but due to a low specificity, it cannot 
replace biopsy.68 
Histological diagnosis of epithelial 
dysplasia has a disadvantage because the 
analysis is based on a static snapshot.13,62 The 
malignant transformation is a dynamic 
process in which several molecular changes 
are taking place simultaneously.  
Optical imaging systems, saliva, and 
exfoliated cells can be used as a source for 
biomarker-based risk assessment.63 Several 
studies have investigated changes as a 
method to identify when dysplastic lesions 
will develop into SCC.13,15,62,69-75 Many 
molecular changes are associated with the 
transformation from dysplasia to malignancy 
in OL and include loss of heterozygosity, 
aberrant DNA expression, dysregulation of 
apoptosis, and altered expression of tissue 
markers.58,62 
Treatment methods 
Various treatment modalities for OL have 
been suggested. Overall, the treatments can 
be categorized as observation, chemotherapy, 
and surgical excision/ablation. Currently, the 
most appropriate treatment remains to be 
found. The outcome of the treatment 
modalities appears to vary, and long-term 
follow-up studies are few. A surgical excision 
has been considered the gold standard with 
regard to the treatment of small local lesions 
with severe dysplasia or carcinoma in situ.13,30 
Recently, the use of cryosurgery, laser 
evaporation, and laser excision has been 
recommended in the literature.39-44,76-79 OL 
with a low to moderate malignant risk may 
either be surgically removed or not.5,13 Non-
dysplastic OL lesions have been shown to 
respond to changes in lifestyle factors such as 
reduction of alcohol and tobacco use.28,66,67 In 
addition, chemoprevention has shown a 
positive effect on precancerous lesions.64 
Non-surgical treatment/chemoprevention 
Non-surgical treatment is a possibility when 
surgical removal is difficult because of, e.g., 
the location of the lesion, its size, or the 
patient’s medical status.57 Overall, the non-
surgical treatment can be divided into 
carotenoids, vitamins, bleomycin, and 
photodynamic therapy. Ribeiro et al.64 
published a review in 2009 on the non-
surgical treatment of OL. RCTs for 
chemotherapy of OL failed to demonstrate an 
effective treatment in preventing 
transformation to SCC and recurrence. No 
recommendation can be provided for specific 
non-invasive and invasive treatments of OL. 
Surgery 
The surgical excision of OL is defined as 
removal of the entire lesion. It is 
recommended that the lesion is excised with 
a margin of 3-5 mm of the clinical normal 
mucosa. The lesion is separated from the 
underlying tissue by blunt dissection. 
Subsequently, the defects are closed directly. 
This can be done by transposition of local 
mucosa flaps or with free mucosal grafts, 
depending on the size of the surgical 
defect.28,34 
Recurrence rates between 0 and 34.4% are 
reported following surgical excision,12,28,31,32,34-
38 and 0-12% of surgically treated lesions 
develop carcinoma within a follow-up period 
of 7-223.2 months.12,28,31,32,34-38 No RCTs have 
been reported so far.80 A retrospective study 
of 269 lesions investigated the long-term 
outcome of premalignant lesions after 
surgical excision and after a follow-up 
without surgery.28 94 lesions were surgically 
removed, and no surgical intervention was 
undertaken in 175 lesions. Malignant 
transformation was seen in 12% of the 
surgically treated lesions after a mean follow-
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up period of 7.5 years, whereas 4% of the 
non-surgical treated lesions transformed 
malignantly after a mean follow-up period of 
6.6 years. The two groups were not directly 
comparable due to a greater number of cases 
of non-homogenous OL, OL with epithelial 
dysplasia, and carcinoma in situ in the group 
that underwent surgical intervention. Thus, 
the study did demonstrate that surgical 
intervention of premalignant lesions did not 
prevent malignant development.28 
Post-operative complications after surgical 
excision of OL are described in the literature 
and include infections, nerve injuries, 
reduction in the mobility of the mouth, 
obstruction of salivary flow, etc.34 In the 
treatment of large OL lesions, surgical 
excision can cause a considerable scar 
contraction during healing with both 
functional and aesthetic consequences.45 In 
addition, the use of skin grafts can interfere 
with proper diagnosis and early signs of 
recurrence.34,45 
Cryosurgery 
A cryosurgery is a treatment option for 
various skin and mucosal diseases. In the 
early 1960s, the method was used as a 
treatment for oral lesions such as hyperplasia, 
angiomas, and leukoplakia.81,82 Cryosurgery 
is a simple, weakly invasive technique in 
which rapid freezing destroys a lesion in 
situ.39,81 
The positive advantages of the therapy 
include a bloodless treatment and a relative 
lack of scarring and pain. In addition, a very 
low incidence of secondary infection has been 
noted.39 Furthermore, it is very safe, relative 
inexpensive, and easy to perform. A 
disadvantage of the therapy is that a biopsy 
should be taken before the OL is treated 
because after treatment the true lesion is 
destroyed. It is non-specific in its destructive 
effects and due to lack of precision; it can be 
difficult to judge the volume of tissue 
necrosis afterward.39,40,67,81 Complications 
include pain, hyperemia, and edema.39-41,67 
The treatment can be done with adjuvant 
therapies and if there is no response to one 
freezing cycle, another cycle can be given.39,81 
In only a few studies has cryosurgery been 
used for the treatment of OL. One study 
treated 60 OL lesions with the use of cotton 
swabs and liquid nitrogen. All lesions 
showed a complete response after an average 
of 6.3 cryosurgeries, and 5 out of 60 OL 
recurred in the follow-up period of 1-5 
months. The recurred lesions underwent 
cryosurgery again. The study demonstrated 
that OL with epithelial dysplasia required a 
significantly fewer number of cryosurgeries 
than lesions without dysplasia.41 The same 
authors investigated the use of cryogun 
cryosurgery in 60 OL lesions. All lesions 
showed complete regression after an average 
of 3.1 treatments. The cryogun therapy 
required fewer treatments to achieve 
complete regression than cryosurgery with 
cotton swabs. Perhaps this can be explained 
by the large amount of liquid nitrogen 
delivered by the cryogun, which maintains a 
constant low temperature, whereas the 
temperature increases quickly with the use of 
cotton swabs.42 
The recurrence of OL after cryosurgery 
has been reported to be 8.3-32.0% after a 
follow-up period of 3-192 months.32,39-42 
Unfortunately, the malignancy rate following 
treatments has, unfortunately, only been 
reported in few studies with numbers 
varying from 0 to 25%.32,40-42 
Laser 
Lasers have been increasingly used in oral 
and maxillofacial surgery since the 1970s, and 
it has become a well-accepted treatment of 
OL.76,77,83 Laser therapy for the treatment of 
OL was first described in 1978.83 It can be 
used for evaporation, excision, and 
coagulation of tissue. The effect of various 
laser types is determined by their wavelength 
and the specific absorption in the tissue. 
Different kinds of lasers have been used for 
oral surgery, including carbon dioxide (CO2), 
neodymium:yttrium-aluminum garnet, and 
potassium-titanyl-phosphate (KTP) lasers. The 
most common and suitable for use in the 
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mouth is the CO2 laser, which generates 
energy at a wavelength of 10.6 µm.22,46 
Laser excision is preferable because it 
allows histological examination, but some 
difficulty in the histopathological 
interpretation can occur because of collateral 
thermal damage.45 Vaporization does not allow 
histological examination of the lesion, and there 
is a risk that small fragments of OL may not be 
completely eliminated by the beam. 
In the literature, several advantages of the 
use of laser in the maxillofacial region have 
been described. The laser affords a 
hemostatic effect by sealing off the blood 
vessels, creating a virtually bloodless field. 
Incision of the oral mucosa can be made with 
minimal bleeding.45,47,78 This is very useful in 
highly vascularized areas. The risk of damage 
to the tissues is small, which reduces acute 
inflammatory reactions and post-operative 
pain, swelling, edema, and infection owing to 
the cauterization of nerve endings and blood 
vessels.45,47,78,84 Wound healing after laser 
treatment is good because of limited tissue 
contraction and produces satisfactory 
mobility of the oral mucosa.47-49,84 There is no 
need for sutures with the laser technique, 
which shortens the surgical time.48,78 
One of the disadvantages with laser 
evaporation is that the lesion is not available 
for histological study. Therefore, an incisional 
biopsy must always be obtained before the 
treatment.67 Wound healing is delayed 
compared with surgical excision and closure 
with sutures because of secondary healing 
with epithelial regeneration. Complete 
healing is described to take around 2-3 
weeks.46 Safety precautions are another 
consideration.78,82 
Post-operative complications after laser 
treatment include pain, bleeding, difficulties 
with speech, paresthesia, difficulty 
swallowing, obstructive swelling of the 
submandibular gland and tethering of the 
tongue. In one study, 78% of patients treated 
by laser reported one or more of these 
complications.50,85 
The recurrence rate of OL after laser 
treatment is 7.0-39.5% within a mean follow-
up period of 1-288 months.21,22,38,43-48,50-56,76 
Recurrence of OL is more likely, especially in 
deeper tissue layers, which are not 
completely eradiated.33 The malignant 
transformation rate has been reported to be 0-
11.4% after a follow-up period of 1-288 
months.21,22,38,43-48,50-56,76 
Few studies have compared the different 
types of lasers. Lim et al.55 compared the use 
of the KTP and CO2 laser in the treatment of 
OL in a retrospectively study of 75 patients. 
No significant difference was found between 
the two groups treated either by KTP or CO2 
laser. A statistically significant reduction in 
recurrence rate was demonstrated in the 
patients treated with the KTP laser  
(P = 0.049). The recurrence rates for the KTP 
and CO2 laser groups were 25.0 and 39.5%. 
The reduction in recurrence might be 
explained by the greater thermal damage 
from the KTP laser. 
Discussion 
One of the approaches for diagnosing SCC is to 
detectoral premalignant lesions and prevent 
their malignant transformation either by 
invasive or non-invasive treatment methods. It 
seems redundant to treat all OL lesions 
surgically, as only 0.13-37% develop into SCC.9-
15 Furthermore, several studies have shown that 
some OL lesions can regress spontaneously 
without any treatment.28,34 It is, therefore, 
important to determine the risk for malignant 
transformation of each OL lesion. 
It is possible to identify lesions with a high 
risk of developing malignancy using the 
clinical and histological picture.11,12,21,24,25,34,79 
Carcinomas may develop in OL lesions with 
no signs of epithelial dysplasia.12,28,32 A study 
showed malignant development in 11-14% of 
lesions exhibiting slight epithelial dysplasia.28 
Instead, clinical characteristics like the 
location, size, and homogeneity of the OL 
may be used to identify risk.11-13,21,24,25,28,62,79  
Another important factor is the reliability 
of the biopsy that is taken for histological 
evaluation. Lack of correlation between 
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histological features and outcome of the 
lesions can probably be explained by the site 
and size of the biopsy. Vedtofte et al.34 found 
that four of 61 OL lesions had superficial 
carcinomas in the excision specimen that 
were undiagnosed in the incisional, pre-
operative biopsy. Lee et al.86 investigated the 
reliability of incisional biopsies. In 200 cases 
receiving a single-site biopsy, 29.5% of the 
patients were underdiagnosed (the definitive 
diagnosis was more serious). Also, 
overdiagnosis (the definitive diagnosis was 
less serious) did occur in 32.9% (with CO2 
laser) and 20.0% (with KTP laser) of their 
biopsies. In 12.0% of the cases, resection 
specimen showed malignancy undetected by 
incisional biopsy. Thus, the study showed 
that incisional biopsies have limitations 
regarding the assessment of OL. Patients 
receiving multiple-site biopsies had 
significantly lower rates of under diagnosis 
and unexpected carcinomas. It is possible to 
histopathologically examine the entire OL 
lesion with an excisional biopsy, but this 
entails the risk of incomplete treatment of 
malignant lesions and overtreatment of 
benign lesions. In general, excisional biopsy 
is not cost-effective.86 Other methods for 
predicting the potential for malignant 
transformation are needed. The use of gene 
markers seems promising as a method of 
assessing the prognosis with regards to 
malignant transformation. Currently, no 
studies have demonstrated methods that are 
applicable for routine diagnostic 
work.13,15,62,69-75 
Several treatment options to prevent OL 
developing into SCC are described in the 
literature. Invasive techniques such as 
surgical excision, cryosurgery, laser excision, 
and laser ablation have been investigated 
with regard to preventing OL from 
developing into carcinoma. Few studies have 
compared the recurrence and malignant 
transformation after treatment between the 
different treatment options.32,40 Significant 
heterogeneity between follow-up studies is 
seen in the literature, which makes it difficult 
to compare the trials.30,62 The definition of 
recurrence differs in different studies, which 
results in different rates of recurrence. Thus, 
it is not possible to determine the influence of 
exposure to causative agents in treated 
patients, and the selection of the proper 
treatment method remains difficult. 
A Cochrane review failed to show a high 
level of evidence regarding an effective 
treatment in preventing OL from 
transforming into carcinomas. Treatments of 
OL can be effective but recurrence and 
adverse effects are common.80 Holmstrup et 
al.28 showed that surgical interventions did 
not prevent all premalignant lesions from 
malignant development. Further, they 
showed a higher rate of malignant 
development of surgically treated OL (13%) 
compared with non-surgically treated lesions 
(4%), which is in contrast to other reported 
study results.12,30-32,34 The two groups in the 
study of Holmstrup et al.28 were not 
completely comparable due to the 
retrospective nature of the study and because 
the groups were not randomized. However, 
they still showed that surgical interventions 
could not prevent OL lesions from 
developing into carcinomas. Further 
investigations are needed.  
Saito et al.32 investigated patients with OL 
who underwent surgical excision, 
cryosurgery, cryosurgery followed by 
surgical excision and observation. The 
malignant transformation rate was lower 
among patients that received surgical excision 
(1.3%) than among patients who underwent 
cryosurgery (25.0%) and among patients who 
did not receive any treatment (7.8%). The study 
groups were not completely comparable 
because of the unequal numbers of patients in 
each group, the number of severe dysplasia 
was higher in the group that underwent 
surgical excision, and the location of OL was 
different between the groups. However, their 
data still indicate that the rate of malignant 
transformation is higher in patients that 
undergo cryosurgery than among patients who 
receive surgical excision in those in whom 
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surgical excision is performed. 
The time for the occurrence of malignant 
transformation in OL is not clear. Pandey et 
al.35 did not show any carcinoma after 
surgical excision 1 year after treatment. 
Holmstrup et al.28 showed that carcinomas 
developed 2.7-15.1 years after surgical 
intervention. In 257 patients with OL, 
Silverman et al.12 found the greatest 
occurrence of malignant transformation in 
the second follow-up year (24%). The 
malignant transformation was also seen 20-39 
years after the initial diagnosis of OL. There 
is currently no consensus regarding the 
treatment and follow-up required for patients 
with OL. Reported follow-up periods vary 
from immediate discharge to lifetime follow-
up.87 However, in general, the literature 
suggests aclose and prolonged follow-up of 
patients who have undergone surgical 
treatment.12,22,28,34,54 
Yang et al.21 investigated the risk for 
recurrence after laser surgery. Patients with 
non-homogenous OL had a higher risk for 
recurrence compared to patients with 
homogenous OL. Lifestyle factors such as 
cigarette smoking and betel quid chewing 
affected the outcome. Patients who did not 
quit smoking cigarettes or chewing betel quid 
were 9.6 and 19.5 times more likely to 
develop recurrence than those who did quit. 
Thus, the curative effect of the treatment is 
not only dependent on the treatment method, 
but also the lifestyle factors, that might serve 
as causative agents. 
In tables 2-4, the recurrence and 
malignancy rates reported in several studies 
of invasive treatments are listed. The rates 
vary between the studies, and as mentioned, 
the study outcomes are not completely 
comparable. The main studies are 
retrospective with small patient groups. It is 
not possible to give specific evidence-based 
recommendations regarding the surgical 
treatment of OL lesions because of a lack of 
RCTs in the literature. In non-RCTs, the 
effectiveness of various surgical interventions 
has resulted in various outcomes. 
Furthermore, the literature contains no 
studies of sufficient quality for evidence-
based recommendations for the use of non-
surgical treatment modalities.  
OL lesions are not lethal in themselves and 
the risk of developing carcinomas is low. 
Therefore, adverse effects and complications in 
the proposed treatment must be kept very low. 
Non-invasive treatments are often preferable 
for the patient. Side effects such as headache, 
muscular pain, erythema, and erosions have 
been reported.80 No study has compared the 
recurrence, the malignancy rate, and the 
objective and subjective (patients) side effects 
and complications of chemotherapy with the 
invasive treatment modalities.  
López-Jornet and Camacho-Alonso49 
compared the pain and swelling after 
removal of OL with CO2 laser and a cold 
knife. They found statistically significant 
differences during the first 3 days after 
treatment. The patients treated with CO2 
laser showed a lower level of post-operative 
pain (P = 0.021) and swelling (P = 0.019) 
compared with the patients treated with 
surgery. The study group was small and the 
follow-up period was brief, but their results 
were interesting and showed that the CO2 
laser could be an interesting alternative to 
conventional surgery, considering the 
apparent reduction of side effects. 
Furthermore, another study showed a 
significant difference in the use of post-
operative analgesic. 90% of the patients 
treated with a conventional surgery used 
analgesics postoperatively, compared to 29% 
patients treated with CO2 laser used them  
(P < 0.001).78 Chee and Sasaki77 compared the 
operating time and blood loss between 
surgical excision and CO2 laser excision in 45 
patients. The visualization of the operative 
field was better in the CO2 group, but there 
was no improvement in operating time. 
Another study reported shorter surgical time 
when CO2 laser was used compared to that 
associated with surgical excision because of 
less bleeding and no need for sutures.78 Thus, 
CO2 laser can be a good alternative to 
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surgical excision owing to its favorable 
features like a clearer surgical field because of 
its hemostatic effect and probably also 
reduced post-operative pain and swelling.49 
So far no study reveals any evidence that 
non-surgical and surgical treatments are 
protective against the malignant 
transformation of OL. There is no evidence of 
the opposite effect either. It appears that 
recurrence and malignant transformation of 
OL might be independent of the treatment 
regime. The number of OL lesions that are 
prevented from development into cancer is 
unknown. A follow-up by the clinician 
responsible for the treatment should be done 
regardless of the treatment. No strict 
guidelines can be given with regard to 
follow-up, but lifelong follow-up is 
recommended at intervals of < 6 months.88 
Conclusion 
The detection, diagnosis, and management of 
OL remain complex. The risk of malignant 
transformation of OL varies from 0.13 to 37% 
depending on location, etiological factors, 
clinical features, and degree of dysplasia. 
Promising technologies for determining the 
risk of malignant transformation are 
currently being investigated. Several medical 
and surgical treatment protocols have been 
recommended. However, no high-level, 
evidence-based study exists that recommends 
one specific treatment. Some treatments of 
OL may be effective in healing but no 
treatments have been shown to be able to 
prevent recurrence and malignant 
transformation. Surgical treatment appears to 
decrease the risk of transformation but does 
not eliminate it. Future research is needed to 
identify better prognostic markers for the 
progression from OL to SCC, a more effective 
and less invasive treatments, and the length 
of follow-up periods. 
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